Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtypes in pigs.
Porcine circovirus type-2b (PCV2b) is the primary global causative agent of porcine circovirus-associated disease (PCVAD). In this study, we first constructed a novel chimeric virus (PCV1-2b) with the PCV2b capsid gene cloned into the backbone of non-pathogenic PCV1. A pathogenicity study conducted in caesarean-derived colostrum-deprived pigs showed that pigs inoculated with PCV1-2b (n=10) had decreased lymphoid lesions and significantly lower viral load at 21 dpi, and significantly lower viremia starting at 14 dpi compared to pigs inoculated with PCV2b (n=10). All PCV1-2b infected pigs remained clinically healthy, while four of ten PCV2b-infected pigs died or were euthanized early due to clinical PCVAD. In a subsequent challenge study, conventional pigs were first vaccinated with PCV1-2b (n=20) or left unvaccinated (n=20), and 10 pigs in each group were then challenged with PCV2a and PCV2b, respectively. Vaccinated pigs had no detectable viremia and significantly decreased overall lymphoid lesion scores and lower viral loads compared to unvaccinated controls. The results indicate the chimeric PCV1-2b virus is a good candidate for a live-attenuated vaccine against both PCV2b and PCV2a subtypes.